Akari Therapeutics (AKTX) Equity Average (2012 - 2026)

Akari Therapeutics has disclosed Equity Average across 14 years of filings, most recently posting $21.4 million for Q1 2026.

• Equity Average for Q1 2026 came in at $21.4 million, down 2.88% year-over-year; the trailing twelve-month figure through Mar 2026 was $21.4 million (down 2.88% YoY), and the FY2025 annual result was $25.3 million, up 129.8% from the prior year.
• Equity Average came in at $21.4 million for Q1 2026 at Akari Therapeutics, down from $25.5 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $25.5 million in Q4 2025 to a low of -$5.2 million in Q3 2024.
• The 5-year median for Equity Average is $4.4 million (2023), against an average of $9.1 million.
• Peak annual rise in Equity Average reached 97193.75% in 2024, while the deepest fall reached 447.26% in 2024.
• Akari Therapeutics' Equity Average stood at $3.7 million in 2022, then tumbled by 100.22% to -$8000.0 in 2023, then soared by 97193.75% to $7.8 million in 2024, then soared by 228.39% to $25.5 million in 2025, then slipped by 16.28% to $21.4 million in 2026.
• The last three Equity Average figures came in at $21.4 million (Q1 2026), $25.5 million (Q4 2025), and $24.1 million (Q3 2025), per Business Quant data.